6:06 PM
Feb 04, 2014
 |  BC Extra  |  Company News

Myriad to acquire Crescendo

Myriad Genetics Inc. (NASDAQ:MYGN) jumped $4.20 (15%) to $31.38 in early after-hours trading on Tuesday after the company reported earnings for the second quarter for its fiscal year ending June 30, 2014, and announced it will acquire Crescendo Bioscience Inc. (South San Francisco, Calif.). Myriad will acquire molecular diagnostics company Crescendo for $245 million in...

Read the full 261 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >